GeoVax Labs In-Licenses Development Rights To Multi-Antigenic COVID-19 Vaccine Candidate

Loading...
Loading...
  • GeoVax Labs Inc GOVX entered into an exclusive license agreement with City of Hope, a cancer research and treatment organization, for COH04S1, a synthetic, attenuated modified vaccinia Ankara vector expressing spike and nucleocapsid antigens of the SARS-CoV-2 virus. 
  • GeoVax has exclusive rights to develop and commercialize a multi-antigenic SARS-CoV-2 vaccine candidate developed at the City of Hope for immunocompromised patients.
  • The financial terms of the transaction were not immediately disclosed.
  • The candidate is currently in Phase 2 trial and has shown potential to be used as a primary and/or general booster vaccine against COVID-19 worldwide.
  • The Phase 2 trial is assessing the safety and immunogenicity of COH04S1 compared to Pfizer Inc PFEBioNTech SE's BNTX vaccine in patients who have previously received either an allogeneic or autologous hematopoietic cell transplant or chimeric antigen receptor (CAR) T cell therapy.
  • Related Link: Why Geovax Labs Shares Are Soaring Today?
  • Price Action: GOVX shares are down 1.19% at $4.19 during the premarket session on the last check Wednesday.
Posted In: BiotechNewsPenny StocksHealth CareContractsGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 2 Trial
We simplify the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...